<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cytoa24545" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cytometry A</journal-id><journal-id journal-id-type="iso-abbrev">Cytometry A</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">CYTO</journal-id><journal-title-group><journal-title>Cytometry</journal-title></journal-title-group><issn pub-type="ppub">1552-4922</issn><issn pub-type="epub">1552-4930</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9310743</article-id><article-id pub-id-type="pmcid-ver">PMC9310743.1</article-id><article-id pub-id-type="pmcaid">9310743</article-id><article-id pub-id-type="pmcaiid">9310743</article-id><article-id pub-id-type="pmid">35274803</article-id><article-id pub-id-type="doi">10.1002/cyto.a.24545</article-id><article-id pub-id-type="publisher-id">CYTOA24545</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Omip</subject></subj-group><subj-group subj-group-type="heading"><subject>Omip</subject></subj-group></article-categories><title-group><article-title>OMIP 083: A 21&#8208;marker 18&#8208;color flow cytometry panel for in&#8208;depth phenotyping of human peripheral monocytes</article-title><alt-title alt-title-type="left-running-head">Hally et al.</alt-title></title-group><contrib-group><contrib id="cytoa24545-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Hally</surname><given-names initials="KE">Kathryn E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3608-3795</contrib-id><xref rid="cytoa24545-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cytoa24545-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cytoa24545-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>kathryn.hally@otago.ac.nz</email></address></contrib><contrib id="cytoa24545-cr-0002" contrib-type="author"><name name-style="western"><surname>Ferrer&#8208;Font</surname><given-names initials="L">Laura</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3131-7233</contrib-id><xref rid="cytoa24545-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cytoa24545-cr-0003" contrib-type="author"><name name-style="western"><surname>Pilkington</surname><given-names initials="KR">Katherine R.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1848-1645</contrib-id><xref rid="cytoa24545-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cytoa24545-cr-0004" contrib-type="author"><name name-style="western"><surname>Larsen</surname><given-names initials="PD">Peter D.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8706-9032</contrib-id><xref rid="cytoa24545-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cytoa24545-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cytoa24545-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="cytoa24545-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Surgery and Anaesthesia</named-content>
<institution>The University of Otago</institution>
<city>Wellington</city>
</aff><aff id="cytoa24545-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">School of Biological Sciences</named-content>
<institution>Victoria University of Wellington</institution>
<city>Wellington</city>
</aff><aff id="cytoa24545-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Wellington Cardiovascular Research Group</institution>
<city>Wellington</city>
</aff><aff id="cytoa24545-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Hugh Green Cytometry Centre</named-content>
<institution>Malaghan Institute of Medical Research</institution>
<city>Wellington</city>
<country country="NZ">New Zealand</country>
</aff><aff id="cytoa24545-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Cytek Biosciences, Inc</institution>
<city>Fremont</city>
<named-content content-type="country-part">California</named-content>
<country country="US">United States</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Kathryn Hally, Department of Surgery and Anaesthesia, University of Otago, 23A Mein Street, Newtown, Wellington, New Zealand.<break/>
Email: <email>kathryn.hally@otago.ac.nz</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>3</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2022</year></pub-date><volume>101</volume><issue seq="60">5</issue><issue-id pub-id-type="pmc-issue-id">413021</issue-id><issue-id pub-id-type="doi">10.1002/cyto.a.v101.5</issue-id><fpage>374</fpage><lpage>379</lpage><history><date date-type="rev-recd"><day>09</day><month>2</month><year>2022</year></date><date date-type="received"><day>14</day><month>10</month><year>2021</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>07</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>29</day><month>07</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-18 21:25:40.813"><day>18</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2022 The Authors. <italic toggle="yes">Cytometry Part A</italic> published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CYTO-101-374.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CYTO-101-374.pdf"/><kwd-group kwd-group-type="author-generated"><kwd id="cytoa24545-kwd-0001">monocytes</kwd><kwd id="cytoa24545-kwd-0002">human immunophenotyping</kwd><kwd id="cytoa24545-kwd-0003">innate immunity</kwd><kwd id="cytoa24545-kwd-0004">full spectrum flow cytometry</kwd><kwd id="cytoa24545-kwd-0005">PBMCs</kwd><kwd id="cytoa24545-kwd-0006">OMIP</kwd></kwd-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="6"/><word-count count="4478"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2022</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:25.07.2022</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cytoa24545-cit-9001"><string-name name-style="western"><surname>Hally</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Ferrer&#8208;Font</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pilkington</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Larsen</surname><given-names>PD</given-names></string-name>. <article-title>OMIP 083: A 21&#8208;marker 18&#8208;color flow cytometry panel for in&#8208;depth phenotyping of human peripheral monocytes</article-title>. <source>Cytometry</source>. <year>2022</year>;<volume>101</volume>:<fpage>374</fpage>&#8211;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.a.24545</pub-id><pub-id pub-id-type="pmid">35274803</pub-id><pub-id pub-id-type="pmcid">PMC9310743</pub-id></mixed-citation>
</p></notes></front><body id="cytoa24545-body-0001"><sec id="cytoa24545-sec-0001"><title>PURPOSE AND APPROPRIATE SAMPLE TYPES</title><p>This 21&#8208;marker, 18&#8208;color panel was developed to accurately delineate monocyte subsets by manual gating and, once successfully gated, to characterize monocyte function in&#8208;depth. This panel was optimized on human peripheral blood mononuclear cells (PBMCs) density&#8208;separated from whole blood drawn into Cyto&#8208;Chex blood collection tubes (BCTs; Streck, La Vista, NE) from healthy adults. All samples were analyzed on a three&#8208;laser (violet&#8208;blue&#8208;red) Aurora full spectrum flow cytometer (Cytek Biosciences, Fremont, CA). Deep phenotyping was achieved by minimizing the number of channels used to exclude nonmonocyte cells and maximizing the number of markers included to monitor monocyte immune status. This panel was specifically designed to interrogate cell&#8208;surface expression of monocyte&#8208;centric antigens to reduce handling time and complexity, which are desirable characteristics of a clinically applicable protocol. Although not tested on cryopreserved PBMCs or with alternative BCTs, we anticipate that this panel could be used on these sample types with minimal optimization. For optimal staining, we recommend the use of density&#8208;separated PBMCs over red blood cell (RBC)&#8208;lysed whole blood. In supplementary material, we highlight our step&#8208;wise troubleshooting to achieve optimal staining of this panel.</p></sec><sec sec-type="background" id="cytoa24545-sec-0002"><label>1</label><title>BACKGROUND</title><p>Acute and chronic inflammatory diseases are often associated with significant risk of progression and recurrence. This risk is amplified by the lack of accurate clinical risk&#8208;stratification tools for prediction of survival from morbidity and mortality. Due to their heterogeneity and plasticity, the role of monocytes in propagating and maintaining many inflammatory diseases is well&#8208;established. Interrogating the dynamics of monocyte phenotype in these clinical contexts may provide a tool both for better understanding of pathology and for predicting disease course. To this end, we have developed a 21&#8208;marker, 18&#8208;color immunophenotyping panel for deep monocyte analysis in human peripheral blood (Table&#160;<xref rid="cytoa24545-tbl-0001" ref-type="table">1</xref>). This is the second optimized multicolor immunofluorescence panel (OMIP) to utilize full spectrum flow cytometry [<xref rid="cytoa24545-bib-0001" ref-type="bibr">1</xref>]. Analysis of the full spectrum of each fluorochrome as well as analysis of the autofluorescence spectrum of cells&#8208;of&#8208;interest allows for the use of fluorochrome combinations that are unable to be differentiated by conventional cytometry and increases the resolution of cell populations [<xref rid="cytoa24545-bib-0002" ref-type="bibr">2</xref>]. Of particular interest to the aims of this OMIP, which contains many markers co&#8208;expressed on monocytes, the reduced level of spreading error seen with full spectrum flow cytometry aided in resolving issues of spread with co&#8208;expressed markers.</p><table-wrap position="float" id="cytoa24545-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Summary table for application of OMIP&#8208;083</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Purpose</th><th align="left" valign="bottom" rowspan="1" colspan="1">Delineation of peripheral monocyte subsets and deep phenotyping of monocyte function.</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Species</td><td align="left" valign="top" rowspan="1" colspan="1">Humans</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cell type</td><td align="left" valign="top" rowspan="1" colspan="1">PBMCs</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cross references</td><td align="left" valign="top" rowspan="1" colspan="1">OMIP&#8208;023, OMIP&#8208;024, OMIP&#8208;034, OMIP&#8208;038, OMIP&#8208;042, OMIP&#8208;069</td></tr></tbody></table></table-wrap><p>Many published OMIPs aim to enumerate many cellular subtypes from blood [<xref rid="cytoa24545-bib-0001" ref-type="bibr">1</xref>, <xref rid="cytoa24545-bib-0003" ref-type="bibr">3</xref>, <xref rid="cytoa24545-bib-0004" ref-type="bibr">4</xref>, <xref rid="cytoa24545-bib-0005" ref-type="bibr">5</xref>, <xref rid="cytoa24545-bib-0006" ref-type="bibr">6</xref>, <xref rid="cytoa24545-bib-0007" ref-type="bibr">7</xref>] (Table&#160;<xref rid="cytoa24545-tbl-0001" ref-type="table">1</xref>). However, there is also a need to focus on deep phenotyping of individual subsets that are implicated in disease progression and survival. While these deep phenotyping panels exist for other peripheral subsets (namely T cells, B cells and dendritic cells [DCs]), there remains room to introduce such a flow cytometry&#8208;based panel for peripheral innate subsets, such as monocytes and neutrophils. Here, we expand on existing OMIPs by presenting a monocyte&#8208;centric panel that is designed to exclude nonmonocyte cells, identify and delineate four monocyte subsets and, once identified, to phenotypically characterize each subset.</p><p>Circulating human monocytes are conventionally divided into three subsets as follows [<xref rid="cytoa24545-bib-0008" ref-type="bibr">8</xref>, <xref rid="cytoa24545-bib-0009" ref-type="bibr">9</xref>]: classical (CD14<sup>++</sup>/CD16<sup>&#8722;</sup>), intermediate (CD14<sup>+</sup>/CD16<sup>+</sup>), and nonclassical (CD14<sup>&#8722;</sup>/CD16<sup>++</sup>). These subsets differ in their function: classical monocytes contribute to the host's pro&#8208;inflammatory defense mechanisms, while intermediate monocytes are attuned toward antigen presentation, and nonclassical monocytes play a role in vascular patrolling and surveillance [<xref rid="cytoa24545-bib-0018" ref-type="bibr">18</xref>, <xref rid="cytoa24545-bib-0019" ref-type="bibr">19</xref>]. Here, we expand on these definitions by further subsetting nonclassical monocytes based on expression of SLAN (6&#8208;sulfo LacNAc), a carbohydrate modification of P&#8208;selectin glycoprotein ligand&#8208;1 (PSGL&#8208;1). Within nonclassical monocytes, we can define a SLAN<sup>+</sup> (CD14<sup>&#8722;</sup>/CD16<sup>++</sup>/SLAN<sup>+</sup>) and a SLAN<sup>&#8722;</sup> (CD14<sup>&#8722;</sup>/CD16<sup>++</sup>/SLAN<sup>&#8722;</sup>) subset [<xref rid="cytoa24545-bib-0010" ref-type="bibr">10</xref>, <xref rid="cytoa24545-bib-0011" ref-type="bibr">11</xref>, <xref rid="cytoa24545-bib-0012" ref-type="bibr">12</xref>, <xref rid="cytoa24545-bib-0013" ref-type="bibr">13</xref>]. SLAN<sup>+</sup> nonclassical monocytes been shown to be both phenotypically and functionally different from their SLAN<sup>&#8722;</sup> counterparts [<xref rid="cytoa24545-bib-0011" ref-type="bibr">11</xref>, <xref rid="cytoa24545-bib-0013" ref-type="bibr">13</xref>]. Originally classified as DCs, SLAN<sup>+</sup> nonclassical monocytes are now recognized as a bona fide monocyte subset [<xref rid="cytoa24545-bib-0014" ref-type="bibr">14</xref>], as transcriptional profiling has indicated their closer relationship with the monocyte compartment than with the DC compartment [<xref rid="cytoa24545-bib-0015" ref-type="bibr">15</xref>]. As such, inclusion of SLAN in this panel offers users the ability to examine this subset, distinct from other nonclassical monocytes. A full list of the antibodies used in this panel is given in Table&#160;<xref rid="cytoa24545-tbl-0002" ref-type="table">2</xref>.</p><table-wrap position="float" id="cytoa24545-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Reagents for OMIP&#8208;083</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Specificity</th><th align="left" valign="bottom" rowspan="1" colspan="1">Fluorochrome</th><th align="left" valign="bottom" rowspan="1" colspan="1">Clone</th><th align="left" valign="bottom" rowspan="1" colspan="1">Purpose</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">CD45</td><td align="left" valign="top" rowspan="1" colspan="1">Alexa Fluor 532</td><td align="left" valign="top" rowspan="1" colspan="1">HI30</td><td align="left" valign="top" rowspan="1" colspan="1">ID leukocytes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD66b</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Dazzle 594</td><td align="left" valign="top" rowspan="1" colspan="1">G10F5</td><td align="left" valign="top" rowspan="1" colspan="1">Exclude neutrophils and eosinophils</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD3</td><td align="left" valign="top" rowspan="1" colspan="1">FITC</td><td align="left" valign="top" rowspan="1" colspan="1">SK7</td><td align="left" valign="top" rowspan="1" colspan="1">Exclude pan&#8208;T cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD123</td><td align="left" valign="top" rowspan="1" colspan="1">FITC</td><td align="left" valign="top" rowspan="1" colspan="1">6H6</td><td align="left" valign="top" rowspan="1" colspan="1">Exclude basophils and pDCs</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD19</td><td align="left" valign="top" rowspan="1" colspan="1">FITC</td><td align="left" valign="top" rowspan="1" colspan="1">SJ25C1</td><td align="left" valign="top" rowspan="1" colspan="1">Exclude B cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD56</td><td align="left" valign="top" rowspan="1" colspan="1">FITC</td><td align="left" valign="top" rowspan="1" colspan="1">HCD56</td><td align="left" valign="top" rowspan="1" colspan="1">Exclude NK cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR2</td><td align="left" valign="top" rowspan="1" colspan="1">PE</td><td align="left" valign="top" rowspan="1" colspan="1">11G7</td><td align="left" valign="top" rowspan="1" colspan="1">ID monocytes, pattern recognition receptor expression</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD14</td><td align="left" valign="top" rowspan="1" colspan="1">BV570</td><td align="left" valign="top" rowspan="1" colspan="1">M5E2</td><td align="left" valign="top" rowspan="1" colspan="1">ID monocyte subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD16</td><td align="left" valign="top" rowspan="1" colspan="1">BV421</td><td align="left" valign="top" rowspan="1" colspan="1">3G8</td><td align="left" valign="top" rowspan="1" colspan="1">ID monocyte subsets, Fc receptor expression</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SLAN</td><td align="left" valign="top" rowspan="1" colspan="1">VioBlue</td><td align="left" valign="top" rowspan="1" colspan="1">DD&#8208;1</td><td align="left" valign="top" rowspan="1" colspan="1">ID monocyte subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCR2</td><td align="left" valign="top" rowspan="1" colspan="1">APC&#8208;Fire 750</td><td align="left" valign="top" rowspan="1" colspan="1">K036C2</td><td align="left" valign="top" rowspan="1" colspan="1">ID monocyte subsets, cytokine receptor expression</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CX3CR1</td><td align="left" valign="top" rowspan="1" colspan="1">PerCP&#8208;Cy5.5</td><td align="left" valign="top" rowspan="1" colspan="1">2A9&#8208;1</td><td align="left" valign="top" rowspan="1" colspan="1">Cytokine receptor expression</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CXCR4</td><td align="left" valign="top" rowspan="1" colspan="1">BV785</td><td align="left" valign="top" rowspan="1" colspan="1">125G</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD36</td><td align="left" valign="top" rowspan="1" colspan="1">VioGreen</td><td align="left" valign="top" rowspan="1" colspan="1">AC106</td><td align="left" valign="top" rowspan="1" colspan="1">Scavenger receptor expression</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD11c</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy5</td><td align="left" valign="top" rowspan="1" colspan="1">3.9</td><td align="left" valign="top" rowspan="1" colspan="1">Adhesion receptor expression</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD11b</td><td align="left" valign="top" rowspan="1" colspan="1">BV650</td><td align="left" valign="top" rowspan="1" colspan="1">ICRF44</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HLA&#8208;DR</td><td align="left" valign="top" rowspan="1" colspan="1">BV480</td><td align="left" valign="top" rowspan="1" colspan="1">G46&#8208;6</td><td align="left" valign="top" rowspan="1" colspan="1">Antigen presentation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD86</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy7</td><td align="left" valign="top" rowspan="1" colspan="1">BU63</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD42b</td><td align="left" valign="top" rowspan="1" colspan="1">APC</td><td align="left" valign="top" rowspan="1" colspan="1">HIP1</td><td align="left" valign="top" rowspan="1" colspan="1">Heterotypic aggregation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD64</td><td align="left" valign="top" rowspan="1" colspan="1">BV605</td><td align="left" valign="top" rowspan="1" colspan="1">10.1</td><td align="left" valign="top" rowspan="1" colspan="1">Fc receptor expression</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD&#8208;1</td><td align="left" valign="top" rowspan="1" colspan="1">BV750</td><td align="left" valign="top" rowspan="1" colspan="1">EH12.2H7</td><td align="left" valign="top" rowspan="1" colspan="1">Examine the PD&#8208;1 pathway</td></tr></tbody></table></table-wrap><p>Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1</xref> demonstrates the gating strategy for excluding nonmonocytes (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1A</xref>) and delineating the four monocyte subsets (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1B</xref>). Six markers across three detectors were designated to exclude nonmonocytes. Nonleukocytes (contaminating platelets and red blood cells) were excluded by gating on CD45<sup>+</sup> cells (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1A</xref>
<bold>, vii</bold>) and granulocytes (neutrophils and eosinophils) were excluded by gating on CD45<sup>+</sup>/CD66b<sup>&#8722;</sup> cells (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1A</xref>
<bold>, viii</bold>). Lineage markers for T cells (CD3), B cells (CD19), Natural Killer cells (CD56), and both plasmacytoid DCs and basophils (CD123) were assigned to the same fluorophore (FITC). As such, monocytes were defined as lineage<sup>&#8722;</sup> (Lin<sup>&#8722;</sup>). In conjunction with these lineage markers, TLR2 was used as a pan&#8208;monocyte marker to pull out a clean monocyte population (TLR2<sup>+</sup>/Lin<sup>&#8722;</sup>) (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1A</xref>
<bold>, ix</bold>). TLR2 is similarly and highly expressed across classical, intermediate and nonclassical monocytes, noted both here and by others [<xref rid="cytoa24545-bib-0016" ref-type="bibr">16</xref>, <xref rid="cytoa24545-bib-0017" ref-type="bibr">17</xref>, <xref rid="cytoa24545-bib-0018" ref-type="bibr">18</xref>]. Similar and high expression across subsets is desirable for a pan marker and, here, eliminates HLA&#8208;DR (variably expressed) and CD86 (dimly expressed) (<xref rid="cytoa24545-supitem-0002" ref-type="supplementary-material">
<bold>Figure S9</bold> of <bold>Data S1</bold>
</xref>), both of which are commonly cited as pan&#8208;monocyte markers elsewhere [<xref rid="cytoa24545-bib-0009" ref-type="bibr">9</xref>, <xref rid="cytoa24545-bib-0019" ref-type="bibr">19</xref>, <xref rid="cytoa24545-bib-0020" ref-type="bibr">20</xref>]. In this panel, the total monocyte population is thus defined as CD45<sup>+</sup>/CD66b<sup>&#8722;</sup>/Lin<sup>&#8722;</sup>/TLR2<sup>+</sup>. At this stage of gating (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1A</xref>
<bold>ix</bold>), we also eliminate Lin<sup>&#8722;</sup>/TLR2<sup>low</sup> cells. As such, we define monocytes as strictly TLR2<sup>+</sup>.</p><fig position="float" fig-type="FIGURE" id="cytoa24545-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Overview of the 21&#8208;marker, 18&#8208;color monocyte&#8208;centric panel on human PBMCs. PBMCs were density&#8208;separated from Cyto&#8208;Chex blood collection tubes (Streck, La Vista, NE), stained and acquired on a 3&#8208;laser Cytek Aurora (Cytek biosciences, Fremont, CA). Initially, the sample is cleaned by excluding variable flow rate during acquisition (typically experienced at the start and end of sample acquisition), doublets, debris and antibody aggregates (A, i&#8208;vi). Following cleaning, CD45<sup>+</sup> (A, vii) and CD66b<sup>&#8722;</sup> (A, viii) leukocytes are sequentially gated. Several lineage markers (CD3, CD19, CD56, CD123) are conjugated to the same fluorochrome to facilitate efficient exclusion of all other nonmonocyte cells (A, ix). Within the same plot that Lin<sup>+</sup> leukocytes are excluded, the monocyte population is defined as TLR2<sup>+</sup> (A, ix). As such, the monocyte population is defined as: CD45<sup>+</sup>/CD66b<sup>&#8722;</sup>/Lin<sup>&#8722;</sup>/TLR2<sup>+</sup>. Monocytes display their characteristic expression of CD14 and CD16 (B, i). Separating classical (CD14<sup>++</sup>/CD16<sup>&#8722;</sup>) monocytes from all other monocyte subsets (CD14<sup>var</sup>/CD16<sup>var</sup>) can be achieved in this plot. From here, classical monocytes are confirmed to display their expected pattern of CCR2 and CX<sub>3</sub>CR1 (B, ii). Residual classical monocytes are defined in B, iii as those cells which were originally gated as &#8216;other monocyte subsets&#8217; from the parent population but which subsequently show CCR2 and CX<sub>3</sub>CR1 expression patterns identical to classical monocytes. This population is removed from downstream analysis. From here, a true population of &#8216;other monocyte subsets&#8217; is defined (B, iii) and subsequently divided into intermediate (CCR2<sup>+</sup>/SLAN<sup>&#8722;</sup>) monocytes and two subsets of nonclassical monocytes based on expression of SLAN: SLAN<sup>+</sup> (CCR2<sup>&#8722;</sup>/SLAN<sup>+</sup>) nonclassical and SLAN<sup>&#8722;</sup> (CCR2<sup>&#8722;</sup>/SLAN<sup>&#8722;</sup>) monocytes (B, iv). High&#8208;dimensional analysis with the UMAP algorithm was conducted on PBMCs from two individuals across three timepoints (for a total of six samples) (C). Data were cleaned (as demonstrated in A, i&#8208;vi) and CD45<sup>+</sup> events from these six samples were combined and used for this analysis. Manual gating of the four monocyte populations was overlaid on this two&#8208;dimensional rendering (C, i). UMAP analysis demonstrates the ease of discriminating the monocyte population from all other leukocytes using TLR2 (C, ii). Heatmap overlays also demonstrate the distinct expression levels of CD14 (C, iii), CD16 (C, iv), CCR2 (C, v), CX<sub>3</sub>CR1 (C, vi) and SLAN (C, vii) within these monocyte populations. Once identified, these four monocyte subsets were interrogated for their expression of a further nine markers (D); each monocyte subset shows distinctive expression profiles</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CYTO-101-374-g001.jpg"/></fig><p>Having defined total monocytes, close attention must be paid to manually gate each monocyte subset, particularly given that each has distinctive functions. This is commonly achieved by visualizing the total monocyte population by CD14 and CD16 expression (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1B</xref>
<bold>i</bold>). The majority of the population is CD14<sup>++</sup>/CD16<sup>&#8722;</sup> (an expression pattern that defines classical monocytes) and the remaining &#8220;tail&#8221; of monocytes (inclusive of both intermediate and nonclassical monocytes) show increasing expression of CD16 and decreasing expression of CD14. The task of manually gating all monocyte subsets by CD14 and CD16 is, thus, difficult as these subsets sit along a gradient of CD14 and CD16 expression. This is a particular problem for defining intermediate monocytes which, by virtue of their name, express an intermediate phenotype between the classical and nonclassical subsets. As such, intermediate monocytes are frequently manually gated from other subsets at an arbitrary level of CD14 and CD16 expression. Our gating strategy accounts for this gradient effect by defining each of the monocyte subsets with a larger set of markers (CD14, CD16, CCR2, CX<sub>3</sub>CR1, SLAN) rather than relying solely on CD14 and CD16 expression.</p><p>Separating classical monocytes from all other monocytes is routinely and accurately achieved by examining CD16 and CD14 expression (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1B</xref>
<bold>i</bold>). As such, classical monocytes are identified as CD45<sup>+</sup>/CD66b<sup>&#8722;</sup>/Lin<sup>&#8722;</sup>/TLR2<sup>+</sup>/CD14<sup>++</sup>/CD16<sup>&#8722;</sup>. All other subsets are defined in this plot as CD14<sup>var</sup>/CD16<sup>var</sup>. We also place a confirmatory gate around this classical monocyte population using both CCR2 and CX<sub>3</sub>CR1 (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1B</xref>
<bold>, ii</bold>): compared to all other monocyte subsets, classical monocytes are CCR2<sup>high</sup>/CX<sub>3</sub>CR1<sup>low</sup>. We additionally apply this confirmatory gate to CD14<sup>var</sup>/CD16<sup>var</sup> monocytes to identify and exclude residual classical monocytes (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1B</xref>
<bold>, iii</bold>). Also within Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1B</xref>
<bold>, iii</bold>, the remaining monocyte subsets (intermediate and nonclassical) are gated as CCR2<sup>low</sup>/CX<sub>3</sub>CR1<sup>high</sup> compared to classical monocytes.</p><p>The next task is accurate separation of intermediate and nonclassical monocyte subsets, which requires markers that are differentially expressed between these populations. Markers that satisfy this requirement include CCR2, CXCR4, CD36, and SLAN. Of particular interest, nonclassical monocytes are well&#8208;cited as negative for CCR2 [<xref rid="cytoa24545-bib-0010" ref-type="bibr">10</xref>, <xref rid="cytoa24545-bib-0011" ref-type="bibr">11</xref>, <xref rid="cytoa24545-bib-0012" ref-type="bibr">12</xref>, <xref rid="cytoa24545-bib-0021" ref-type="bibr">21</xref>, <xref rid="cytoa24545-bib-0022" ref-type="bibr">22</xref>, <xref rid="cytoa24545-bib-0023" ref-type="bibr">23</xref>], CXCR4 [<xref rid="cytoa24545-bib-0021" ref-type="bibr">21</xref>, <xref rid="cytoa24545-bib-0023" ref-type="bibr">23</xref>] and CD36 [<xref rid="cytoa24545-bib-0021" ref-type="bibr">21</xref>, <xref rid="cytoa24545-bib-0022" ref-type="bibr">22</xref>, <xref rid="cytoa24545-bib-0024" ref-type="bibr">24</xref>], whereas intermediate monocytes show variable expression of all three markers. The nonclassical phenotype can therefore be described as CCR2<sup>&#8722;</sup>/CXCR4<sup>&#8722;</sup>/CD36<sup>&#8722;</sup>, and are phenotypically distinct from all other monocyte subsets, which can be described as CCR2<sup>var</sup>/CXCR4<sup>var</sup>/CD36<sup>var</sup>. As described earlier, the addition of SLAN also allows for discrimination of two nonclassical populations (SLAN<sup>+</sup> vs. SLAN<sup>&#8722;</sup>). In our hands, CCR2 worked best for identifying nonclassical (CCR2<sup>&#8722;</sup>) away from intermediate (CCR2<sup>+</sup>) monocytes, compared to both CXCR4 and CD36 (<xref rid="cytoa24545-supitem-0002" ref-type="supplementary-material">
<bold>Figure S11</bold> of <bold>Data S1</bold>
</xref>) and were therefore defined as shown in Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1B</xref>
<bold>, iv</bold>. Intermediate monocytes are thus identified as CD45<sup>+</sup>/CD66b<sup>&#8722;</sup>/Lin<sup>&#8722;</sup>/TLR2<sup>+</sup>/CD14<sup>+</sup>/CD16<sup>+</sup>/CX<sub>3</sub>CR1<sup>low</sup>/CCR2<sup>+</sup>. In conjunction with SLAN, CCR2<sup>&#8722;</sup> nonclassical monocytes could be further delineated into SLAN<sup>+</sup> (CD45<sup>+</sup>/CD66b<sup>&#8722;</sup>/Lin<sup>&#8722;</sup>/TLR2<sup>+</sup>/CD14<sup>&#8722;</sup>/CD16<sup>++</sup>/CX<sub>3</sub>CR1<sup>low</sup>/CCR2<sup>&#8722;</sup>/SLAN<sup>+</sup>) and SLAN<sup>&#8722;</sup> (CD45<sup>+</sup>/CD66b<sup>&#8722;</sup>/Lin<sup>&#8722;</sup>/TLR2<sup>+</sup>/CD14<sup>&#8722;</sup>/CD16<sup>++</sup>/CX<sub>3</sub>CR1<sup>low</sup>/CCR2<sup>&#8722;</sup>/SLAN<sup>&#8722;</sup>) subsets. Based on <bold>Figure</bold>
<xref rid="cytoa24545-fig-0001" ref-type="fig">
<bold>1</bold>
<bold>A,B</bold>
</xref>, all four monocyte subsets can be defined using 12 markers (CD45, CD66b, CD3, CD19, CD56, CD123, TLR2, CD14, CD16, CCR2, CX<sub>3</sub>CR1, SLAN) across nine detectors. In Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1B</xref>
<bold>, i</bold>, there is a population of CD14<sup>low</sup>CD16<sup>&#8722;</sup>; these cells are excluded from analysis as their expression pattern of both CD14 and CD16 is uncharacteristic of monocytes.</p><p>CD45<sup>+</sup> events from each of six PBMC samples were combined to visualize the four manually gated monocyte subsets using the UMAP algorithm (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1C</xref>
<bold>, i</bold>) [<xref rid="cytoa24545-bib-0025" ref-type="bibr">25</xref>]. Heatmap overlays for TLR2, CD14, CD16, CCR2, CX<sub>3</sub>CR1, and SLAN (Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1C</xref>
<bold>, ii&#8208;vii</bold>) demonstrate the differential expression patterns across the four monocyte subsets. In Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1C</xref>
<bold>, i and ii</bold>, we can see that TLR2<sup>low</sup> cells are excluded from analysis; strictly TLR2<sup>+</sup> cells are defined as monocytes.</p><p>Having identified these four subsets, we can interrogate various effector functions including: 1) heterotypic aggregation (CD42b), 2) adhesion (CD11b, CD11c), 3) pattern recognition (TLR2), 4) antigen presentation (HLA&#8208;DR, CD86), 5) the PD&#8208;1 pathway (PD&#8208;1), 6) chemokine receptor expression (CCR2, CX<sub>3</sub>CR1, CXCR4), 7) Fc receptor expression (CD16, CD64) and 8) scavenging receptor expression (CD36). The expression patterns of these markers across each monocyte subset are shown in Figure&#160;<xref rid="cytoa24545-fig-0001" ref-type="fig">1D</xref>. This is a nonexhaustive list but provides a broad overview of monocyte function. If users were interested in probing other functions, we suggest using the 12 core markers for defining each subset and, from here, any markers of interest could be swapped in or, in the case of additional lasers, added alongside the functional markers listed above.</p><p>Optimization was conducted on peripheral blood anticoagulated and preserved in Cyto&#8208;Chex BCTs (Streck). Preserving at the time of blood draw allows for a &#8216;snapshot&#8217; of cellular phenotyping that is not provided by other BCTs, where storage time before processing may influence live cell phenotyping. The use of a preservative eliminates the use of a viability dye in this panel (<xref rid="cytoa24545-supitem-0002" ref-type="supplementary-material">
<bold>Figure S3</bold> of <bold>Data S1</bold>
</xref>) but, if other BCTs were used, we suggest that Zombie&#8208;NIR (BioLegend, San Diego, CA) could be added to this panel without further optimization. As our ultimate goal is to use this panel for assessing monocyte immune status as it relates to disease course in our model of interest, we prioritized the use of this BCT over more traditional anticoagulants (e.g., ethylenediaminetetraacetic acid [EDTA]). This allows for potentially extended times between blood draw and processing, which is the type of flexibility required for clinical blood processing. However, cells collected in these tubes, being preserved, are not appropriate for downstream functional assays. We believe this panel could be used on blood anticoagulated with EDTA or another anticoagulant of choice with minimal optimization, which would provide the opportunity to interrogate monocytes <italic toggle="yes">in vitro</italic> if required by the user.</p><p>Troubleshooting of this panel centered on four aspects: 1) optimizing a core panel that is crucial for enumerating each monocyte subset, 2) choice of reagents used during isolation and staining of cells, 3) investigating sequential staining for selected markers, and 4) investigating alternative fluorochrome choices where necessary. To clearly present this information to the reader, we have constructed two supplementary materials.&#160;<xref rid="cytoa24545-supitem-0002" ref-type="supplementary-material">
<bold>Data S1</bold>
</xref> focuses on panel optimization and marker&#8208;fluorochrome selection. <xref rid="cytoa24545-supitem-0003" ref-type="supplementary-material">
<bold>Data S2</bold>
</xref> focuses on the steps taken to optimize the staining pattern of a subset of monocyte&#8208;centric markers included in this 21&#8208;marker, 18&#8208;color panel. During troubleshooting, particular attention was paid to optimizing staining of CD16, a crucial monocyte marker, which was ultimately resolved by systematically reviewing alternative fluorochromes, staining reagents and the protocol for isolating cells from peripheral blood (Figures S1&#8211;S4 of <xref rid="cytoa24545-supitem-0003" ref-type="supplementary-material">
<bold>Data S2</bold>
</xref>). Second to this, alternative staining protocols were trialed for the three cytokine receptors (CCR2, CX<sub>3</sub>CR1, CXCR4) as well as CD14 and, ultimately, these four markers were sequentially stained to achieve optimal results (<xref rid="cytoa24545-supitem-0003" ref-type="supplementary-material">
<bold>Figures S5</bold> and <bold>S6</bold> of <bold>Data S2</bold>
</xref>). We also outline our decision regarding which single&#8208;stained controls (cell versus beads) should be used for unmixing this monocyte&#8208;centric panel (<xref rid="cytoa24545-supitem-0002" ref-type="supplementary-material">
<bold>Figures S14&#8211;S16</bold> of <bold>Data S1</bold>
</xref>). The final staining protocol is outlined in <xref rid="cytoa24545-supitem-0002" ref-type="supplementary-material">
<bold>Section S15</bold> of <bold>Data S1</bold>
</xref>.</p><p>In summary, our 21&#8208;marker, 18&#8208;color monocyte&#8208;centric panel is designed to identify four peripheral monocyte subsets and interrogate monocyte phenotype across a wide range of functional pathways. This panel consists of a core of 12 markers across nine fluorochromes (CD45, CD66b, CD3, CD19, CD56, CD123, TLR2, CD14, CD16, CCR2, CX<sub>3</sub>CR1, and SLAN) to delineate these subsets and a further nine markers (CXCR4, CD36, CD11c, CD11b, HLA&#8208;DR, CD86, CD42b, CD64, PD&#8208;1) can be used to probe monocyte immune status across eight unique functional pathways (Table&#160;<xref rid="cytoa24545-tbl-0002" ref-type="table">2</xref>). This panel has broad applicability to study inflammatory conditions that are known to induce changes in monocyte phenotype and can be used to determine the clinical utility of deep monocyte phenotyping for predicting disease course.</p><sec id="cytoa24545-sec-0003"><label>1.1</label><title>Similarity to published <styled-content style="fixed-case" toggle="no">OMIPs</styled-content>
</title><p>Several published OMIPs (OMIP&#8208;023 [<xref rid="cytoa24545-bib-0003" ref-type="bibr">3</xref>], OMIP&#8208;024 [<xref rid="cytoa24545-bib-0004" ref-type="bibr">4</xref>], OMIP&#8208;034 [<xref rid="cytoa24545-bib-0005" ref-type="bibr">5</xref>], OMIP&#8208;038 [<xref rid="cytoa24545-bib-0006" ref-type="bibr">6</xref>], OMIP&#8208;042 [<xref rid="cytoa24545-bib-0007" ref-type="bibr">7</xref>], OMIP&#8208;069 [<xref rid="cytoa24545-bib-0001" ref-type="bibr">1</xref>]), which broadly aim to characterize major leukocyte subsets in human peripheral blood, gate on the monocyte population. Most gate on the monocyte population using one or a combination of CD14 and HLA&#8208;DR (OMIP&#8208;023 [<xref rid="cytoa24545-bib-0003" ref-type="bibr">3</xref>], OMIP&#8208;024 [<xref rid="cytoa24545-bib-0004" ref-type="bibr">4</xref>], OMIP&#8208;034 [<xref rid="cytoa24545-bib-0005" ref-type="bibr">5</xref>], OMIP&#8208;038 [<xref rid="cytoa24545-bib-0006" ref-type="bibr">6</xref>], OMIP&#8208;042 [<xref rid="cytoa24545-bib-0007" ref-type="bibr">7</xref>]). Similarly, most also identify the three monocyte populations (classical, intermediate, nonclassical) using both CD14 and CD16 (OMIP&#8208;023 [<xref rid="cytoa24545-bib-0003" ref-type="bibr">3</xref>], OMIP&#8208;024 [<xref rid="cytoa24545-bib-0004" ref-type="bibr">4</xref>], OMIP&#8208;038 [<xref rid="cytoa24545-bib-0006" ref-type="bibr">6</xref>], OMIP&#8208;069 [<xref rid="cytoa24545-bib-0001" ref-type="bibr">1</xref>]). Here, we expand on these definitions for each monocyte subset, provide an alternative gating strategy for identifying these subsets and demonstrate how this panel can be utilized to analyze monocyte phenotype in&#8208;depth.</p></sec><sec id="cytoa24545-sec-0004"><label>1.2</label><title>Human subjects</title><p>Whole blood was obtained from healthy volunteers under ethical approval (19/CEN/129) by the Health and Disability Ethics Committee, New Zealand.</p></sec></sec><sec id="cytoa24545-sec-0007"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Kathryn E. Hally:</bold> Conceptualization (lead); data curation (lead); formal analysis (equal); writing &#8211; original draft (lead); writing &#8211; review and editing (equal). <bold>Laura Ferrer&#8208;Font:</bold> Conceptualization (supporting); data curation (supporting); formal analysis (equal); writing &#8211; original draft (supporting); writing &#8211; review and editing (equal). <bold>Katherine R. Pilkington:</bold> Conceptualization (supporting); data curation (supporting); formal analysis (equal); writing &#8211; original draft (supporting); writing &#8211; review and editing (equal). <bold>Peter D. Larsen:</bold> Conceptualization (supporting); data curation (supporting); formal analysis (equal); writing &#8211; original draft (supporting); writing &#8211; review and editing (equal).</p></sec><sec sec-type="COI-statement" id="cytoa24545-sec-0006"><title>CONFLICT OF INTEREST</title><p>Katherine Pilkington is an employee of Cytek Biosciences, Inc., the manufacturer of the Aurora full spectrum flow cytometer used in this manuscript.</p></sec><sec id="cytoa24545-sec-0008"><label>2</label><sec id="cytoa24545-sec-0009"><title>PEER REVIEW</title><p>The peer review history for this article is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://publons.com/publon/10.1002/cyto.a.24545" ext-link-type="uri">https://publons.com/publon/10.1002/cyto.a.24545</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cytoa24545-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>MIFlowCyt</bold>: MIFlowCyt Item Checklist.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-374-s001.doc" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24545-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Appendix</bold>
<bold>S1</bold>: Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-374-s003.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24545-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Appendix</bold>
<bold>S2</bold>: Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-374-s002.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cytoa24545-sec-0005"><title>ACKNOWLEDGMENTS</title><p>The authors thank Cytek Biosciences, Inc., for kindly supplying test size antibody vials for the initially proposed panel. This work was enabled by the Hugh Green Cytometry Centre and the authors thank the Hugh Green Foundation for their contribution. Open access publishing facilitated by University of Otago, as part of the Wiley &#8211; University of Otago agreement via the Council of Australian University Librarians. Open access funding enabled and organized by Projekt DEAL.</p></ack><ref-list id="cytoa24545-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="cytoa24545-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0001"><string-name name-style="western"><surname>Park</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Lannigan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jaimes</surname><given-names>MC</given-names></string-name>. <article-title>OMIP&#8208;069: forty&#8208;color full Spectrum flow cytometry panel for deep Immunophenotyping of major cell subsets in human peripheral blood</article-title>. <source>Cytometry A</source>. <year>2020</year>;<volume>97</volume>(<issue>10</issue>):<fpage>1044</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">32830910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.24213</pub-id><pub-id pub-id-type="pmcid">PMC8132182</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0002"><string-name name-style="western"><surname>Niewold</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ashhurst</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>NJC</given-names></string-name>. <article-title>Evaluating spectral cytometry for immune profiling in viral disease</article-title>. <source>Cytometry A</source>. <year>2020</year>;<volume>97</volume>(<issue>11</issue>):<fpage>1165</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">32799382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.24211</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0003"><string-name name-style="western"><surname>Bocsi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Melzer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>D&#228;hnert</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>T&#225;rnok</surname><given-names>A</given-names></string-name>. <article-title>OMIP&#8208;023: 10&#8208;color, 13 antibody panel for in&#8208;depth phenotyping of human peripheral blood leukocytes</article-title>. <source>Cytometry A</source>. <year>2014</year>;<volume>85</volume>(<issue>9</issue>):<fpage>781</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">25132115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22505</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0004"><string-name name-style="western"><surname>Moncunill</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Doba&#241;o</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>McElrath</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>De Rosa</surname><given-names>SC</given-names></string-name>. <article-title>OMIP&#8208;024: pan&#8208;leukocyte immunophenotypic characterization of PBMC subsets in human samples</article-title>. <source>Cytometry A</source>. <year>2014</year>;<volume>85</volume>(<issue>12</issue>):<fpage>995</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25352070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22580</pub-id><pub-id pub-id-type="pmcid">PMC4457440</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0005"><string-name name-style="western"><surname>Baumgart</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Peddinghaus</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schulte&#8208;Wrede</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Mei</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Gr&#228;tzkau</surname><given-names>A</given-names></string-name>. <article-title>OMIP&#8208;034: comprehensive immune phenotyping of human peripheral leukocytes by mass cytometry for monitoring immunomodulatory therapies</article-title>. <source>Cytometry A</source>. <year>2017</year>;<volume>91</volume>(<issue>1</issue>):<fpage>34</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27362704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22894</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0006"><string-name name-style="western"><surname>Smolen</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kollmann</surname><given-names>TR</given-names></string-name>. <article-title>OMIP&#8208;038: innate immune assessment with a 14 color flow cytometry panel</article-title>. <source>Cytometry A</source>. <year>2017</year>;<volume>91</volume>(<issue>10</issue>):<fpage>966</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28419701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.23109</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0007"><string-name name-style="western"><surname>Staser</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Eades</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Karpova</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>DiPersio</surname><given-names>JF</given-names></string-name>. <article-title>OMIP&#8208;042: 21&#8208;color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood</article-title>. <source>Cytometry A</source>. <year>2018</year>;<volume>93</volume>(<issue>2</issue>):<fpage>186</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29288606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.23303</pub-id><pub-id pub-id-type="pmcid">PMC6077845</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0008"><string-name name-style="western"><surname>Ziegler&#8208;Heitbrock</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ancuta</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Crowe</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dalod</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Grau</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>DN</given-names></string-name>, et al. <article-title>Nomenclature of monocytes and dendritic cells in blood</article-title>. <source>Blood</source>. <year>2010</year>;<volume>116</volume>(<issue>16</issue>):<fpage>e74</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">20628149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-02-258558</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0009"><string-name name-style="western"><surname>Weber</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shantsila</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hristov</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Caligiuri</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Guzik</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Heine</surname><given-names>GH</given-names></string-name>, et al. <article-title>Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups "Atherosclerosis &amp; Vascular Biology" and "Thrombosis"</article-title>. <source>Thromb Haemost</source>. <year>2016</year>;<volume>116</volume>(<issue>4</issue>):<fpage>626</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">27412877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1160/TH16-02-0091</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0010"><string-name name-style="western"><surname>Cros</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cagnard</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Woollard</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Patey</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Senechel</surname><given-names>B</given-names></string-name>, et al. <article-title>Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors</article-title>. <source>Immunity</source>. <year>2010</year>;<volume>33</volume>(<issue>3</issue>):<fpage>375</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">20832340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2010.08.012</pub-id><pub-id pub-id-type="pmcid">PMC3063338</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0011"><string-name name-style="western"><surname>Roussel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ferrell</surname><given-names>PB</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Greenplate</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Lhomme</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Le Gallou</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Diggins</surname><given-names>KE</given-names></string-name>, et al. <article-title>Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid&#8208;derived suppressor cells from human blood and bone marrow</article-title>. <source>J Leukoc Biol</source>. <year>2017</year>;<volume>102</volume>(<issue>2</issue>):<fpage>437</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">28400539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.5MA1116-457R</pub-id><pub-id pub-id-type="pmcid">PMC6608074</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0012"><string-name name-style="western"><surname>Wong</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Tai</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sem</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yeap</surname><given-names>WH</given-names></string-name>, et al. <article-title>Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets</article-title>. <source>Blood</source>. <year>2011</year>;<volume>118</volume>(<issue>5</issue>):<fpage>e16</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">21653326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-12-326355</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0013"><string-name name-style="western"><surname>Hamers</surname><given-names>AAJ</given-names></string-name>, <string-name name-style="western"><surname>Dinh</surname><given-names>HQ</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Marcovecchio</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Blatchley</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nakao</surname><given-names>CS</given-names></string-name>, et al. <article-title>Human monocyte heterogeneity as revealed by high&#8208;dimensional mass cytometry</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2019</year>;<volume>39</volume>(<issue>1</issue>):<fpage>25</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">30580568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.118.311022</pub-id><pub-id pub-id-type="pmcid">PMC6697379</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0014"><string-name name-style="western"><surname>Ahmad</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>D&#246;bel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schmitz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sch&#228;kel</surname><given-names>K</given-names></string-name>. <article-title>Current concepts on 6&#8208;sulfo LacNAc expressing monocytes (slanMo)</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>(<issue>948</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00948</pub-id><pub-id pub-id-type="pmcid">PMC6540605</pub-id><pub-id pub-id-type="pmid">31191513</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0015"><string-name name-style="western"><surname>van Leeuwen&#8208;Kerkhoff</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lundberg</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Westers</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Kordasti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bontkes</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>de Gruijl</surname><given-names>TD</given-names></string-name>, et al. <article-title>Transcriptional profiling reveals functional dichotomy between human slan+ non&#8208;classical monocytes and myeloid dendritic cells</article-title>. <source>J Leukoc Biol</source>. <year>2017</year>;<volume>102</volume>(<issue>4</issue>):<fpage>1055</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">28720687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.3MA0117-037R</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0016"><string-name name-style="western"><surname>Shirk</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Kral</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Gama</surname><given-names>L</given-names></string-name>. <article-title>Toll&#8208;like receptor 2(bright) cells identify circulating monocytes in human and non&#8208;human primates</article-title>. <source>Cytometry A</source>. <year>2017</year>;<volume>91</volume>(<issue>4</issue>):<fpage>364</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">28323396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.23098</pub-id><pub-id pub-id-type="pmcid">PMC5516202</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0017"><string-name name-style="western"><surname>Sabroe</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Usher</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Whyte</surname><given-names>MKB</given-names></string-name>, <string-name name-style="western"><surname>Dower</surname><given-names>SK</given-names></string-name>. <article-title>Toll&#8208;like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses</article-title>. <source>J Immunol</source>. <year>2002</year>;<volume>168</volume>(<issue>9</issue>):<fpage>4701</fpage>.<pub-id pub-id-type="pmid">11971020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.168.9.4701</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0018"><string-name name-style="western"><surname>Kurt&#8208;Jones</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Mandell</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Whitney</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Padgett</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gosselin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Newburger</surname><given-names>PE</given-names></string-name>, et al. <article-title>Role of toll&#8208;like receptor 2 (TLR2) in neutrophil activation: GM&#8208;CSF enhances TLR2 expression and TLR2&#8208;mediated interleukin 8 responses in neutrophils</article-title>. <source>Blood</source>. <year>2002</year>;<volume>100</volume>(<issue>5</issue>):<fpage>1860</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12176910</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0019"><string-name name-style="western"><surname>Heimbeck</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hofer</surname><given-names>TPJ</given-names></string-name>, <string-name name-style="western"><surname>Eder</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Frankenberger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Marei</surname><given-names>A</given-names></string-name>, et al. <article-title>Standardized single&#8208;platform assay for human monocyte subpopulations: lower CD14+CD16++ monocytes in females</article-title>. <source>Cytometry A</source>. <year>2010</year>;<volume>77A</volume>(<issue>9</issue>):<fpage>823</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.20942</pub-id><pub-id pub-id-type="pmid">20662093</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0020"><string-name name-style="western"><surname>Zawada</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Rogacev</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Schirmer</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Sester</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>B&#246;hm</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fliser</surname><given-names>D</given-names></string-name>, et al. <article-title>Monocyte heterogeneity in human cardiovascular disease</article-title>. <source>Immunobiology</source>. <year>2012</year>;<volume>217</volume>(<issue>12</issue>):<fpage>1273</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">22898391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imbio.2012.07.001</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0021"><string-name name-style="western"><surname>Mueller</surname><given-names>KAL</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Ehinger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Baas</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gawaz</surname><given-names>MP</given-names></string-name>, et al. <article-title>Loss of CXCR4 on non&#8208;classical monocytes in participants of the Women's interagency HIV study (WIHS) with subclinical atherosclerosis</article-title>. <source>Cardiovasc Res</source>. <year>2019</year>;<volume>115</volume>(<issue>6</issue>):<fpage>1029</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">30520941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvy292</pub-id><pub-id pub-id-type="pmcid">PMC6735712</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0022"><string-name name-style="western"><surname>Tallone</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Turconi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Soldati</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pedrazzini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Moccetti</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Vassalli</surname><given-names>G</given-names></string-name>. <article-title>Heterogeneity of human monocytes: an optimized four&#8208;color flow cytometry protocol for analysis of monocyte subsets</article-title>. <source>J Cardiovasc Transl Res</source>. <year>2011</year>;<volume>4</volume>(<issue>2</issue>):<fpage>211</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21308491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12265-011-9256-4</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0023"><string-name name-style="western"><surname>Shantsila</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Wrigley</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tapp</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Apostolakis</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Montoro&#8208;Garcia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Drayson</surname><given-names>MT</given-names></string-name>, et al. <article-title>Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology</article-title>. <source>J Thromb Haemost</source>. <year>2011</year>;<volume>9</volume>(<issue>5</issue>):<fpage>1056</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">21342432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1538-7836.2011.04244.x</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0024"><string-name name-style="western"><surname>Mukherjee</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kanti Barman</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kumar Thatoi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tripathy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumar Das</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ravindran</surname><given-names>B</given-names></string-name>. <article-title>Non&#8208;classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematous</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>(<issue>1</issue>):<fpage>13886</fpage>.<pub-id pub-id-type="pmid">26358827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep13886</pub-id><pub-id pub-id-type="pmcid">PMC4566081</pub-id></mixed-citation></ref><ref id="cytoa24545-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cytoa24545-cit-0025"><string-name name-style="western"><surname>McInnes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Healy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Saul</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gro&#223;berger</surname>, <given-names>L</given-names></string-name>. <article-title>UMAP: uniform manifold approximation and projection</article-title>. <source>J Open Source Softw</source>. <year>2018</year>;<volume>3</volume>(<issue>29</issue>):<fpage>861</fpage>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>